Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.35 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27220640 | 0.98 | CHRM2 (0.41) | CHRM2CYP2D6NFKB1KMT2ABLM | |
| SCHEMBL2174381 | 0.98 | CHRM2 (0.41) | CHRM2CYP2D6NFKB1KMT2ABLM | |
| Ammonia Solution, Strong SCHEMBL22716834 | 0.98 | CHRM2 (0.37) | CHRM2CYP2D6NFKB1KMT2ABLM | |
| SCHEMBL2125590 | 0.98 | CHRM2 (0.41) | CHRM2CYP2D6NFKB1KMT2ABLM | |
| SCHEMBL146038 | 0.98 | CHRM2 (0.41) | CHRM2CYP2D6NFKB1KMT2ABLM | |
| SCHEMBL2121005 | 0.98 | CHRM2 (0.41) | CHRM2CYP2D6NFKB1KMT2ABLM | |
| Hydrochloric Acid SCHEMBL6157108 | 0.96 | CHRM2 (0.40) | CHRM2CYP2D6NFKB1KMT2ABLM | |
| SCHEMBL838329 | 0.94 | KMT2A (0.36) | CYP2D6NFKB1KMT2ABLMNPSR1 | |
| SCHEMBL5452674 | 0.85 | CHRM2 (0.42) | CHRM2KMT2ABLMNPSR1LMNA | |
| SCHEMBL246225 | 0.85 | MEN1 (0.34) | KMT2ALMNAMEN1ALDH1A1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082069-A1 | COMPOUND BINDING TO CRBN PROTEIN AND DEGRADATION AGENT OF PROTEIN | 中国海洋大学 | 2025-04-24 | — | — | WO | disclosed |
| CN-119841843-A | Compound combined with CRBN protein and degradation agent of CRBN protein | 中国海洋大学 | 2025-04-18 | — | — | CN | disclosed |
| WO-2025036132-A1 | COMPOUND AND USE THEREOF | 中国海洋大学 | 2025-02-20 | — | — | WO | disclosed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| EP-4450490-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | Prazer Therapeutics Inc. (KR) | 2024-10-23 | — | — | EP | disclosed |
| US-20240317711-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| WO-2022270987-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | (주) 업테라 | 2022-12-29 | — | — | WO | disclosed |
| US-11141368-B2 | Cosmetic composition, cosmetic treatment method, kit, and compound | L'OREAL (FR) | 2021-10-12 | — | — | US | disclosed |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| US-10813866-B2 | Cosmetic composition, cosmetic treatment method, kit, and compound | L'OREAL (FR) | 2020-10-27 | — | — | US | disclosed |
| WO-2011112441-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | MERCK SHARP & DOHME CORP. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110142856-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-7951816-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | disclosed |
| US-7736624-B2 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | UNIV VANDERBILT (US) | 2010-06-15 | — | — | US | disclosed |
| EP-2040699-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | Vanderbilt University Medical Center (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080171740-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2007149456-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1457483-A1 | Cationic lipids with serine backbone | Ruhr-Universität Bochum (DE) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | BRD4, BET1, BRD3 | CHRM2 2974/4885CYP2D6 4618/4885NFKB1 167/4885 |
| US-20080171740-A1 | Chemical Compounds | CXCR4, CCR5, CXCR3 | CHRM2 3518/4885CYP2D6 4282/4885NFKB1 223/4885 |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | CHRM2 4140/4885CYP2D6 4094/4885NFKB1 860/4885 |
| US-10813866-B2 | Cosmetic composition, cosmetic treatment method, kit, and compound | KRT18, KIT, TYR | CHRM2 1528/4885CYP2D6 2413/4885NFKB1 2700/4885 |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | CHRM2 2656/4885CYP2D6 3121/4885NFKB1 998/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | CHRM2 2612/4885CYP2D6 1020/4885NFKB1 409/4885 |
| US-20240317711-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | STUB1, AURKA, XIAP | CHRM2 4289/4885CYP2D6 4182/4885NFKB1 540/4885 |
| US-11141368-B2 | Cosmetic composition, cosmetic treatment method, kit, and compound | KRT18, KIT, TYR | CHRM2 1528/4885CYP2D6 2413/4885NFKB1 2700/4885 |
| US-20110142856-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | CXCR4, CCR5, CXCL12 | CHRM2 758/4885CYP2D6 1226/4885NFKB1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.